Overview

Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload

Status:
Completed
Trial end date:
2019-12-19
Target enrollment:
Participant gender:
Summary
Safety, tolerability, and acceptability of twice-daily dosing with deferiprone delayed-release (DR) tablets in patients with systemic iron overload.
Phase:
Phase 2
Details
Lead Sponsor:
ApoPharma
Treatments:
Deferiprone